Sermorelin

Sermorelin acetate is a 29-amino acid truncated analog of endogenous growth hormone-releasing hormone (GHRH 1-44), representing the shortest fragment of GHRH known to retain full biological activity. It belongs to the GHRH-analog peptide class and was originally developed by Serono Laboratories. The FDA approved sermorelin (as Geref) for diagnostic assessment of GH secretory capacity in children with suspected growth hormone deficiency, and it was later explored therapeutically before the branded pharmaceutical was withdrawn from the US market in 2008 for commercial rather than safety reasons. It now exists in a regulatory grey zone: available through compounding pharmacies in the US under specific prescriber oversight, but also widely sold as an unregulated research chemical by peptide vendors — a distinction that carries meaningful legal and quality implications.

Sermorelin's mechanism of action is meaningfully different from exogenous recombinant human growth hormone (rhGH). Rather than bypassing the hypothalamic-pituitary axis entirely, sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating endogenous GH synthesis and release. This preserves negative feedback mechanisms — meaning the body's own regulatory systems remain intact, theoretically limiting the risk of supraphysiological GH levels. Research suggests this pulsatile, physiologically regulated GH release is qualitatively distinct from rhGH injections, though whether this translates to a meaningfully different safety or efficacy profile in human populations remains an open question.

The evidence base for sermorelin is broader than for many peptides in the research-chemical space, though it is important to distinguish evidence tiers carefully. Human clinical trials do exist: a frequently cited randomized controlled trial by Vittone et al. (1997) in healthy older men reported modest improvements in sleep quality, lean body mass, and GH pulse amplitude, though sample sizes were small (n=89) and effect sizes were not dramatic. Additional human data from compounding-pharmacy-adjacent clinical practice suggests sermorelin may support GH axis function in adults with diagnosed GH deficiency, but robust Phase III RCT data in healthy aging populations is sparse. Animal models have demonstrated more pronounced effects on GH secretion, muscle preservation, and metabolic parameters. A substantial portion of the circulating evidence comes from self-reported user data in biohacker and anti-aging communities, which should be weighted accordingly — not dismissed, but clearly labeled as anecdotal.

Dosing ranges reported in published research and clinical compounding contexts — presented here strictly as research reference points, NOT as a recommendation for human use — have typically ranged from 200mcg to 500mcg administered subcutaneously, most commonly in the evening to align with endogenous GH pulse timing. Some clinical protocols have used doses up to 1mg. Research in adult populations has examined both daily and pulsatile dosing schedules. Cycle durations in clinical literature have ranged from 3 to 6 months. This information is reported from research contexts only. Peptide Guides does not recommend any dosing protocol, and sermorelin sourced outside a licensed compounding pharmacy or prescriber relationship is not approved for human use.

In the United States, sermorelin occupies a nuanced legal position: it is not a DEA-scheduled substance, and licensed compounding pharmacies can legally prepare it for patients under a valid prescription. However, sermorelin sourced from unregulated research-chemical vendors is not intended for human use, is not subject to pharmaceutical-grade manufacturing standards, and exists outside any regulatory approval framework. In the UK and EU, sermorelin is not MHRA- or EMA-approved and is generally classified as an unregulated research chemical. In Australia, it falls under TGA scheduling as a controlled substance requiring prescription. Researchers sourcing sermorelin should prioritize vendors providing comprehensive Certificates of Analysis from accredited third-party laboratories, with HPLC purity data (ideally >98%), mass spectrometry confirmation of molecular identity, and endotoxin testing. The absence of any of these should be treated as a disqualifying red flag. This content is provided for educational purposes only and does not constitute medical advice.